The rarity of sarcoma complicates clinical trial design and biomarker-driven treatment, explains Alexander Spira, MD, PhD, ...

Vaccine news shaping the 2026-2027 immunization season includes major acquisitions, a key FDA panel vote, and new data on ...

Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, ...

From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today. He also explored when a triplet regimen—acalabrutinib, ...

As oncology care becomes increasingly complex with the introduction of targeted therapies, oncology pharmacists are playing a larger role in translating emerging evidence into clinical practice. Kang: ...

Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...

Reimbursement uncertainty and absent permanent billing codes remain dominant CGT access barriers, exposing limitations of “buy-and-bill” models and necessitating dedicated staffing and early ...

Development is moving to phase 2 LEGION-100-2a (NCT06533644) across global sites, with planned neoadjuvant prostate studies and expansion concepts in multiple solid tumors. Metastatic ...

This segment focuses on the clinical implications of the SERENA-6 trial and its evaluation of circulating tumor DNA–guided treatment switching in hormone receptor–positive, HER2-negative metastatic ...

The STAND Act (HR 6835) expands spinal cord injury care via annual preventive evaluations and improved access to prosthetics and assistive mobility devices for eligible veterans. The Travel Assistance ...

Increasing frontline covalent BTK inhibitor use and emerging BTKi+BCL2i+anti-CD20 triplets constrain the R/R BTK-naïve ...

Key Takeaways. Caregiver fear and availability meaningfully influence patient willingness to pursue CAR T and other immune effector therapies, contributing to persistently low uti ...